A rational approach for the development of reduced‐size analogues of neuropeptide Y with high affinity to the Y<sub>1</sub> receptor
Beate Rist(University of California, San Francisco), Annette G. Beck‐Sickinger(Leipzig University of Applied Sciences), H. Wieland(Pharmazeutische Fabrik Dr. Reckeweg (Germany)), Klaus‐Dieter Willim(Pharmazeutische Fabrik Dr. Reckeweg (Germany))
Cited by 30
Related Papers
XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors
|Pharmacological Reviews|1998|893
GPR39 Signaling Is Stimulated by Zinc Ions But Not by Obestatin
|Endocrinology|2006|432
Herbal drugs and phytopharmaceuticals
|Pharmaceutica Acta Helvetiae|1995|415
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226
|European Journal of Pharmacology|1994|374